Oxygenta Pharmaceutical (524636) Q4 10/11 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 10/11 earnings summary
2 Nov, 2026Executive summary
FY2010-11 net loss was Rs. 15.05 lakh, versus Rs. 15.55 lakh in FY2009-10; operations had been at a standstill since 20 Oct 2006 amid a management dispute.
The present management reported regaining possession on 16 May 2012 and spending over Rs. 300 lakh to restore damaged machinery and equipment.
Financial highlights
Net loss after tax was Rs. 15.05 lakh in FY2010-11, compared with Rs. 15.55 lakh in FY2009-10; reported expenses were Rs. 15.05 lakh.
Net loss carried forward rose to Rs. 132.85 crore-equivalent?
Outlook and guidance
Revival plans included renewing licenses and pursuing contract manufacturing; management expressed confidence in resolving issues and improving performance.
A draft revival scheme proposed up to Rs. 4 crore of promoter funding; the next BIFR hearing was scheduled for 11 Apr 2013.
Latest events from Oxygenta Pharmaceutical
- Q2 revenue more than doubled YoY as the pre-tax loss narrowed.524636
Q2 26/27 - Revenue grew, losses narrowed, and post-fire recovery remained the central challenge.524636Q4 15/16
- A ₹166.96 lakh loss accompanied a costly revival and a July 2013 production target.524636Q4 12/13
- Working-capital shortages constrained operations as FY17 losses widened to ₹5.81 crore.524636Q4 16/17
- Production resumed, but losses deepened amid heavy revival funding and significant audit and legal risks.524636Q4 13/14
- Fire-driven disruption widened FY15 losses; production resumed, with breakeven targeted for November 2015.524636Q4 14/15
- Plant restoration began after repossession, but legal and financial risks remained substantial.524636Q4 11/12
- A Rs 15.55 lakh FY10 loss met a revival plan after management regained the factory.524636Q4 09/10
- Factory shutdowns and disputes drove a Rs 25.34m FY06 net loss.524636Q4 05/06